SHAREHOLDERS'/STOCKHOLDERS' (DEFICIT) EQUITY (Tables)

3 Months Ended

Mar. 31, 2025

The following table presents a reconciliation of the beginning and ending balances in Total shareholders’ deficit (in thousands):


	Euro Deferred Shares		Ordinary Shares		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Shareholders’ Deficit


BALANCE, DECEMBER 31, 2023 (PREDECESSOR)	$	44	$	24	$	8,980,561	$	(15,354,427)	$	(223,762)	$	(6,597,560)
Net loss	—		—		—		(154,230)		—		(154,230)
Other comprehensive loss	—		—		—		—		(2,924)		(2,924)



Other	(1)		—		—		—		—		(1)
BALANCE, MARCH 31, 2024 (PREDECESSOR)	$	43	$	24	$	8,980,561	$	(15,508,657)	$	(226,686)	$	(6,754,715)

The following table presents a reconciliation of the beginning and ending balances in Total stockholders’ equity (in thousands):


	Preferred Stock		Common Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity


BALANCE, DECEMBER 31, 2024 (SUCCESSOR)	$	—	$	76	$	1,986,133	$	(730,864)	$	(3,007)	$	1,252,338
Net loss	—		—		—		(128,630)		—		(128,630)
Other comprehensive loss	—		—		—		—		(665)		(665)
Compensation related to share-based awards	—		—		3,180		—		—		3,180



BALANCE, MARCH 31, 2025 (SUCCESSOR)	$	—	$	76	$	1,989,313	$	(859,494)	$	(3,672)	$	1,126,223

Endo, Inc. 10-Q